Pharmaceutical Executive
Even though FDA officials and company executives maintain that Purdue Pharma hasn't violated any rules governing pharma advertising, critics who want to ban the sale of the painkiller OxyContin complain about the company's promotional excesses. At a hearing before the Senate Health, Education, Labor and Pensions (HELP) Committee in February, patient advocates blamed soaring abuse of the medication on company sales and advertising activities.
Even though FDA officials and company executives maintain that Purdue Pharma hasn't violated any rules governing pharma advertising, critics who want to ban the sale of the painkiller OxyContin complain about the company's promotional excesses. At a hearing before the Senate Health, Education, Labor and Pensions (HELP) Committee in February, patient advocates blamed soaring abuse of the medication on company sales and advertising activities.
John Jenkins, director of the Office of New Drugs at FDA's Center for Drug Evaluation and Research, pointed out that Purdue has directed all its marketing for OxyContin to health professionals and not to consumers. There was one letter from FDA's Division of Drug Marketing, Advertising, and Communications in May 2000 complaining about false and misleading claims in an Oxy journal ad, but Purdue halted the promotion.
Paul Goldenheim, Purdue's vice-president of research, said the company trains its sales force to promote responsible prescribing of OxyContin and established a telephone hotline last July for physicians to report "inappropriate" actions by reps. Purdue also put a cap on commissions linked to any single high-prescribing doctor.
Jenkins and several health experts testified to the value of OxyContin in helping patients control chronic pain and to the importance of having a range of pain-control therapies to meet various medical needs. Richard Payne of Memorial Sloan-Kettering Cancer Center in New York pointed out that OxyContin's controlled-release formulation is an effective option for patients who cannot tolerate oral morphine. FDA has worked with Purdue to strengthen label warnings and to educate physicians and patients about ways to curb misuse and abuse of the therapy. The agency believes that the benefits of OxyContin outweigh the risks, Jenkins concluded.
The long-term solution to OxyContin abuse may be to reformulate the product, adding an opioid antagonist that blocks the "high" abusers get by crushing the sustained release tablet before consuming it. Purdue has launched clinical studies to see if adding another active ingredient compromises the product's effectiveness or exposes patients to additional adverse events. Even if the new product is safe and effective, the blocking action of the test formulation works only when taken by injection or snorting-not orally. Reformulation may help curb abuse, commented Wesley Clark of the Substance Abuse Mental Health Services Administration, but he expects that abusers will figure out how to defeat the blocker.
The Weight-Loss Gold Rush: Legal and Regulatory Implications
July 11th 2024Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, what needs to be done for GLP-1s to be covered, advice for investors and financiers considering entering the weight-loss medication market and more.
Healthcare Marketing Strategies for Reaching Diverse Audiences
May 14th 2024Amanda Powers-Han, Chief Marketing Officer, Greater Than One, and Pharmaceutical Executive Editorial Advisory Board member, discusses how improved DE&I in healthcare marketing strategies can not only reach diverse audiences more effectively but also contribute to improved patient care outcomes, challenges faced in crafting culturally sensitive messages, and much more.